Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Bolsa de Madrid  >  Almirall, S.A.    ALM   ES0157097017

ALMIRALL, S.A.

(ALM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
Communiqués de presse de la société ALMIRALL, S.A.
02/06ALMIRALL S A : partners with Plug and Play to accelerate digital innovation in d..
PU
01/15ALMIRALL S A : to participate in J.P. Morgan Healthcare Conference in San Franci..
PU
01/09ALMIRALL S A : signs a strategic agreement with 23andMe to license rights of a b..
PU
01/09ALMIRALL S A : and WuXi Biologics sign strategic collaboration agreement for mul..
PU
01/08ALMIRALL S A : enters into an option agreement to acquire Bioniz Therapeutics an..
PU
2019ALMIRALL S A : and Iktos announce research collaboration in Artificial Intellige..
PU
2019ALMIRALL S A : Volker Koscielny, new Chief Medical Officer and new member of the..
PU
2019ALMIRALL : Exercises its Option with Dermira to License Rights to Lebrikizumab i..
AQ
2019ALMIRALL : NICE publishes final recommendation for Almirall's ILUMETRI®▼ (..
PU
2019ALMIRALL : recognized as distinguished Corporate Leader by American Skin Associa..
PU
2019ALMIRALL : FDA approves Duaklir, a new drug application for chronic obst..
PU
2019ALMIRALL : and HitGen will develop novel oral compounds in atopic dermatitis
PU
2019ALMIRALL : NICE provisionally approves Almirall's ILUMETRI®▼ (tildrakizuma..
PU
2019ALMIRALL : Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two ..
PU
2019ALMIRALL : Nuevolution Partnership Achieves First Collaboration Milestone for De..
PU
2019ALMIRALL : Full-Year 2018 Results
PU
2019ALMIRALL : AlmirallShare, a successful platform to find innovative solutions in ..
PU
2019ALMIRALL : S.A. to present at J.P. Morgan Healthcare Conference in San Francisco
PU
2018ALMIRALL : announces that the Phase III trial of P-3058 for onychomycosis achiev..
PU
2018ALMIRALL : and X-Chem will collaborate to develop oral compounds for dermatologi..
PU
2018ALMIRALL : builds the largest self-consumption photovoltaic plant in Catalonia
PU
2018ALMIRALL : First European consensus on clinical use of dimethyl fumarate
PU
2018ALMIRALL : launches ILUMETRI® in Germany for moderate-to-severe chronic plaque p..
PU
2018ALMIRALL 9M 2018 BUSINESS RESULTS : Strong business momentum
PU
2018ALMIRALL : launches AKASI App, an innovative calculator to assess actinic kerato..
PU
2018ALMIRALL : and the Barcelona Supercomputing Center to collaborate in SilicoDerm ..
PU
2018ALMIRALL : LLC Launches New Name at Fall Clinical Dermatology Congress
PU
2018ALMIRALL : seeks novel targets for skin health
PU
2018ALMIRALL : FDA approves Seysara™, a New Chemical Entity for moderate to se..
PU
2018ALMIRALL : closes agreement with Allergan and acquires its US medical dermatolog..
PU
2018ALMIRALL : The European Commission approves Almirall's ILUMETRI® (tildrakizumab)..
PU
2018ALMIRALL : Tildrakizumab demonstrates lasting efficacy and safety through 3 year..
PU
2018ALMIRALL : and Evotec enter into research collaboration in the field of dermatol..
PU
2018ALMIRALL : Transformational Transaction - Almirall to acquire US medical dermato..
PU
2018ALMIRALL : Strong H1 2018 business results - Upgrading EBITDA Guidance
PU
2018ALMIRALL : announces that both phase III trials of KX2-391 for actinic keratosis..
PU
2018ALMIRALL : seeks new compounds to improve skin health
PU
2018ALMIRALL : Q1 2018. Encouraging Financial Results
PU
2018ALMIRALL : European dermatologists discuss the newest therapies and innovations ..
PU
2018ALMIRALL : Full-Year 2017 Results
PU
2017ALMIRALL : Phase IV ASCENT trial shows Tudorza reduces COPD exacerbations and de..
PU
2017ALMIRALL : Q3 results 2017
PU
2017ALMIRALL : New randomized controlled study confirms the efficacy and tolerabilit..
PU
2017ALMIRALL : Phase III AMPLIFY study shows Duaklir significantly improves lung fun..
PU
2017ALMIRALL : appoints Peter Guenter as new CEO
PU
2017ALMIRALL : announces Ron Menezes as new President & General Manager at Aqua Phar..
PU
2017ALMIRALL'S H1 RESULTS 2017 : reiterating recent Guidance
PU
2017ALMIRALL : collaborates with ICMAB-CSIC and Leitat Technology Center in Nanomedi..
PU
2017ALMIRALL : announces Guidance Update for 2017
PU
2017ALMIRALL : The European Commission (EC) approves Almirall's Skilarence® for mode..
PU
2017ALMIRALL : International experts elaborate a consensus on the effects, present a..
PU
2017ALMIRALL : and LEO Pharma join forces to advance dermatology research by setting..
PU
2017ALMIRALL : Q1 results 2017, driven by Dermatology in Europe
PU
2017ALMIRALL : Receives Positive CHMP Opinion for Dimethyl Fumarate for the Treatmen..
PU
2017ALMIRALL : and Sun Pharma Announce Regulatory Filing of Tildrakizumab in Europe
PU
2017ALMIRALL : Data from Tildrakizumab Clinical Development Program Presented at the..
PU
2016ALMIRALL : and Mercachem announce a collaboration for the development of cytokin..
PU
2016ALMIRALL : and Nuevolution enter into a Strategic Collaboration to Develop ROR&g..
PU
2016ALMIRALL 9M RESULTS 2016 : Strong Derma performance in EU and solid progress in ..
PU
2016ALMIRALL : announces a restructuring plan in Spain
PU
2016ALMIRALL : to Announce Late-Breaking Results for Investigational IL-23p19 inhibi..
PU
2016ALMIRALL : announces positive phase III results showing efficacy of LAS41008 (di..
PU
2016ALMIRALL : announces a global licensing agreement with Patagonia for congenital ..
PU
2016ALMIRALL : and Sun Pharma enter into a License Agreement for Tildrakizumab in Eu..
PU
2016ALMIRALL H1 RESULTS 2016 : Growth in Total Revenues and Net Sales driven by Derm..
PU
2016ALMIRALL' : ‘Shared Skin Initiative' wins a Silver Lion Award at the Canne..
PU
2016ALMIRALL : It is estimated that up to 10% of Actinic Keratosis may advance to sq..
PU
2016ALMIRALL : US distribution agreement between Almirall's Thermigen and Sinclair
PU
2016ALMIRALL : and Bicosome enter into a collaboration and sublicense agreement for ..
PU
2016ALMIRALL'S Q1 RESULTS 2016 : on track to achieve yearly guidance
PU
2016ALMIRALL : reduces its accident rate by 69% in Spain in 2015
PU
2016ALMIRALL : Full-Year 2015 results: Normalized Net Income growth of 90%
PU
2016ALMIRALL : closes the acquisition of ThermiGen LLC entering the aesthetics marke..
PU
2016ALMIRALL : exercises call option to acquire 100% of ThermiGen LLC
PU
2015ALMIRALL : reaches an agreement to acquire 100% of Poli Group
PU
1  2Next
Upcoming event on ALMIRALL, S.A.